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Patients with chronic obstructive pulmonary
disease have shorter survival but superior
endovascular outcomes after endovascular
aneurysm repair
Moqueet A. Qureshi, MD,a Roy K. Greenberg, MD,a,b Tara M. Mastracci, MD,a
Matthew J. Eagleton, MD,a and Adrian V. Hernandez, MD, PhD,a,c Cleveland, Ohio
Objective: This study determined the effect of pulmonary disease on outcomes after endovascular abdominal (EVAR) and
endovascular thoracoabdominal aortic aneurysm (eTAAA) repair.
Methods:A prospective study of high-risk patients undergoing EVAR and eTAAA repair between 1998 and 2009was used
to contrast clinical and endovascular outcomes between patients with (group 1) and without (group 2) chronic
obstructive pulmonary disease (COPD). COPD patients were classified in accordance with the severity of their pulmonary
disease using the Global Initiative for Chronic Obstructive Lung Disease criteria. Survival, morphologic changes, and
complications were assessed using Cox models and life-table analyses. The cause and timing of deaths between the groups
was compared.
Results: Of 905 patients analyzed, 289 (32%) had COPD (group 1) and the remaining patients (group 2) did not have
COPD. EVARwas performed in 334 patients (37%), and fenestrated or branched devices were used in the remaining 571
(63%). Group 1 patients were younger (73.5  6.7 vs 75.6  8.2 years), had a better glomerular filtration rate (67.8 
25.8 vs 61.0  23.3 mL/min/1.73 m2), had higher hematocrits (41.6  5.0 vs 40.5  4.6), and had more extensive
aneurysms. Mean follow-up was 39.5 30.9 months. Early (3% vs 3%) and late (2% vs 1%) aneurysm-related deaths were
similar between the two groups. Survival in group 1 depended on the severity of disease. Survival in patients with Global
Initiative for Chronic Obstructive Lung Disease classification I and II was similar to group 2. Those with classifications
III and IV demonstrated lower survival rates. Relevant pulmonary function test variables included a lower forced
expiratory volume in 1 second and forced expiratory flow in the middle 50%, which were associated with decreased
survival. Surrogate endovascular outcome analyses demonstrated that group 1 patients had fewer endoleaks (20% vs 25%;
P  .05) and more rapid sac shrinkage rate (1.66 mm/y difference; P < .001).
Conclusions: The perioperative risk of death between COPD patients and non-COPD patients is eliminated when
endovascular techniques are used. Long-term survival in COPD patients is most strongly related to the severity of their
disease, and forced expiratory volume in 1 second and forced expiratory flow in the middle 50% are reasonable indicators
of poor long-term outcomes. Morphologic changes after EVAR and eTAAA repair are more favorable in COPD patients,
with a lower endoleak rate and faster sac shrinkage. (J Vasc Surg 2012;56:911-9.)
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fChronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death among Americans.1 Severe
COPD and dependence on home oxygen are perceived as
relative contraindications to major abdominal surgery,2
particularly when conventional repair requires a thoracoab-
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http://dx.doi.org/10.1016/j.jvs.2012.02.055ominal incision resulting in increased perioperative pul-
onary risk.3 However, patients with COPD have an
ncreased prevalence of abdominal aortic aneurysms
AAA)4-6 and have a greater risk of rupture, even in the
etting of small aneurysms,7 underscoring the need for
reatment of this patient population.
The critical clinical decision in such patients is whether
atients will die of complications from their lung disease or
upture of an untreated aneurysm. Thus, the expected risk
f complications in COPD patients must be established,
nd the long-term outcome of such patients should be
ssessed in the context of factors measured during preop-
rative testing. The application of endovascular aneurysm
epair (EVAR) to mitigate risks in such patients8 has been
reviously described and makes logical sense given the lack
f need for large incisions that may detrimentally affect
ulmonary function, among other factors. But the ability to
o such procedures with limited perioperative morbidity
ust be viewed in the context of the longer-term benefits
or pulmonary patients. Furthermore, given the knowledge
hat the presence of COPD has the potential to alter the
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October 2012912 Qureshi et algrowth and rupture risk of untreated aneurysms, the effect
of pulmonary disease on the behavior of the aortic sac after
EVAR or endovascular thoracoabdominal aortic aneurysm
(eTAAA) repair must be examined.
METHODS
A prospectively collected database was analyzed for
patients who underwent EVAR for infrarenal, juxtarenal,
and TAA during 11 years, from 1998 to 2009. Patients
were enrolled into one of two physician-sponsored investi-
gational device exemption trials, one for infrarenal aneu-
rysms8 and one for juxtarenal/TAAs.9,10 All patients were
considered high risk for open surgical repair10 and signed
an informed consent, approved by our Institutional Review
Board (National Institutes of Health trial numbers: NCT-
005834141 [Infrarenal] and NCT-00583050 [Juxtare-
nal/thoracoabdominal]). Patients undergoing emergency
repair were excluded.
Definition and classification of COPD
When preoperative pulmonary function tests were
available. Pulmonary function tests (PFTs) were evaluated,
and the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria, defined by the World Health
Organization, were used to define and classify patients with
COPD11 (Table I):
● The American Thoracic Society acceptability and re-
producibility standards for spirometry were applied to
all patients,12
● Postbronchodilator values were used for evaluation,
and
● COPD was confirmed when a patient with symptoms
Table I. Classification of chronic obstructive pulmonary
disease severity using the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria
Stage PFTs Characteristics
Stage I: Mild Yes FEV1/FVC0.7
FEV180% percent predicted
No Patient not on medications
Stage II: Moderate Yes FEV1/FVC 0.7
FEV1 50%-80% predicted
No Patient taking 1 or 2 classes of
BD
Stage III: Severe Yes FEV1/FVC 0.7
FEV1 30%-50% predicted
No Patient on inhaled steroids in
addition to BD
Stage IV: Very severe Yes FEV1/FVC 0.7
FEV1 30% predicted or
FEV1 50% predicted plus
chronic respiratory failurea
No Patient on home oxygen
BD, Bronchodilators; FEV1, forced expiratory volume in 1 second; FVC,
forced vital capacity; PFT, pulmonary function test.
aRespiratory failure: arterial partial pressure of oxygen 8.0 kPa (60 mm
Hg) with or without arterial partial pressure of carbon dioxide.6.7 kPa (50
mm Hg) while breathing air at sea level.compatible with COPD, including chronic cough and tshortness of breath, was found to have nonreversible
airflow obstruction, defined as forced expiratory vol-
ume in 1 second (FEV1)/forced vital capacity (FVC)
ratio 0.70, and there was no alternative explanation
for the symptoms and airflow obstruction (such as
bronchiectasis).
When preoperative PFTs were not available. The
ollowing criteria were used to identify patients with suffi-
ient evidence to diagnose COPD:
● Patients on supplemental home oxygen with no other
explanation (eg, heart failure, obstructive sleep apnea)
and a physician diagnosis of COPD,
● Patients taking one to three classes of bronchodilators
or anti-inflammatory inhalers (anticholinergics, -
agonists, and inhalational steroids), or both, with no
other explanation (such as pulmonary fibrosis) and a
physician diagnosis of COPD, and
● Patients who were not taking any medications for
COPD at the time of the procedure but had a note by
a pulmonologist or primary care physician, or both,
identifying that they had COPD that had been previ-
ously evaluated with PFTs.
All patients considered to have COPD were classified
nto four grades of severity using the GOLD treatment
uidelines and criteria that have been detailed in Table I.
ariables studied
Patients were grouped by those with COPD (group 1)
nd those without COPD (group 2). Preoperative variables
ollected included demographics, cardiovascular risk fac-
ors, PFT results, medications, maximum aortic diameter,
nd extent of the required aortic repair. Patients were
rouped by smoking status as previous smoker, current
moker, or never smoked.
Three-dimensional modalities used in computed to-
ography angiography, including multiplanar recon-
tructions and centerline of flow analyses, were used to
easure the maximum diameter of the aneurysm sac and
he presence of endoleaks at all intervals in accordance
ith the Society for Vascular Surgery (SVS) reporting
tandards.13,14
The extent of aortic repair was defined as infrarenal,
uxtarenal, and thoracoabdominal. Thoracoabdominal re-
air was further stratified using the Crawford classifica-
ion.15 Preoperative arterial blood gas values were not
nalyzed because they were only available for a small num-
er of patients. Also recorded was the method of anesthesia
dministration (general, epidural or monitored sedation)
nd all factors related to pulmonary function postopera-
ively (time to extubation, need for reintubation, or trache-
stomy need). Overall length of stay and number of days in
he intensive care unit were also assessed.
utcomes
The primary outcome for this study was all-cause mor-
ality. Deaths were classified in accordance with the SVS
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fAvailable in 279 COPD and 596 non-COPD patients.
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Volume 56, Number 4 Qureshi et al 913reporting standards.13,14 In addition to the review of med-
ical records and quarterly phone calls, an automated query
of the United States Social Security Death Index, per-
formed every 3 months, was used to supplement results.
The cause of death was confirmed by a review of state-
issued death certificates, hospital death summaries, autopsy
results, and discussion with family members. Additional
analyses included an assessment of pulmonary and nonpul-
monary deaths between the two groups. Sac size change,
endoleaks, and the need for secondary endovascular inter-
ventions directed at the aortic repair were also compared
between the two groups.
Statistical analysis
All data were captured and stored in a database (Oracle
Clinical 4.03, Redwood Shores, Calif). S-plus 7.0 software
(Insightful, Wash) was used for all statistical analysis. Con-
tinuous variables were expressed as mean  SD and cate-
goric variables as number (percentage). Differences of vari-
ables between the two groups were tested with the t-test for
continuous variables and the 2 test for categoric variables.
Kaplan-Meier curves were used to analyze differences be-
tween the two groups with respect to survival and freedom
from secondary interventions.
The association between the presence of COPD or
other preoperative variables (demographic and clinical) and
overall mortality was evaluated using the Cox model. Mul-
tivariable analysis was done with those variables associated
with death with a P  .2 in the univariable analysis. A
variable with a P  .05 in the multivariable analysis was
considered independently associated with death. A similar
analysis was done to find factors associated with a high
mortality within the COPD cohort. A propensity score
analysis was done to eliminate any differences and the effect
of any confounding variables (such as smoking). The linear
mixed model was used to analyze differences in aortic
diameters with time.
RESULTS
Demographics and preoperative characteristics
We identified 905 patients, 289 with COPD (group 1)
and 616 without COPD (group 2). Of these, 334 (37%)
underwent infrarenal, 218 (24%) juxtarenal, and 353 (39%)
TAA repair. The mean aneurysm diameter was similar
between the two groups (6.5  1.3 vs 6.4  1.3 cm; P 
.4). Table II outlines the differences between the two
groups. Most notably, patients in the COPD group were
younger, had a higher glomerular filtration rate (GFR), had
a higher hematocrit, and had more extensive aneurysms
than non-COPD patients. Smoking, lung cancer, and the
need for supplemental oxygen were more common in
group 1, whereas hypertension and the use of -blockers
were less frequently noted. The distribution of severity of
COPD among men and women within the COPD cohort
was similar (P  .9).able II. Patient demographics and preoperative
haracteristics
haracteristicsa
COPD No COPD
P(n  289) (n  616)
ge, years 73.5  6.7 75.6  8.2 .0002
ale sex 225 (78) 530 (86) .002
moking 266 (98) 497 (87) .0001
Currently smoking 68 (25) 103 (18) .00001
Former smokers 198 (73) 394 (69)
ardiovascular
Diabetes 47 (16) 113 (18) .4
History of
Coronary artery
disease 109 (38) 264 (43) .1
Hypertension 210 (73) 489 (79) .02
Cerebrovascular
disease 45 (16) 116 (19) .2
Peripheral vascular
disease 24 (8) 56 (9) .7
Ejection fractionb 49.1  13.8 48.6  14.9 .7
Ejection fraction
30b 18 (11) 44 (14) .5
ulmonary
FEV1
c 1.5  0.6 2.2  0.6 .0001
FEV1 1 L
c 42 (26) 0 .00002
FEF25%-75%
d 0.6  0.4 1.5  0.9 .00001
FEF25%-75% 30%
of expectedd 120 (75) 6 (11) .00001
Use of oxygen at
home 126 (44) 18 (3) .00001
History of lung
cancer 13 (5) 11 (2) .02
ody mass index,e
kg/m2 26.2  8.9 26.1  8.2 .9
FR, mL/min/1.73
m2 67.8  25.8 61.0  23.3 .0001
40 mL/min/
1.73 m2 38 (13) 107 (17) .1
60 mL/min/
1.73 m2 110 (38) 309 (50) .0008
ematocrit 41.6  5.0 40.5  4.6 .003
ortic diameter, cmf 6.5  1.3 6.4  1.3 .4
xtent of aneurysm
repair
TAAA I 12 (4) 11 (2) .05
TAAA II 22 (8) 24 (4)
TAAA III 27 (9) 69 (11)
TAAA IV 60 (21) 128 (21)
Juxtarenal 73 (25) 145 (24)
Infrarenal 95 (33) 239 (39)
edications
Aspirin 155 (54) 371 (60) .1
-Blockers 125 (43) 353 (57) .0001
Statins 155 (54) 338 (55) .8
OPD, chronic obstructive pulmonary disease; FEF25%-50%, forced expira-
ory flow in the middle 50%; FEV1, forced expiratory volume in 1 second;
FR, glomerular filtration rate; TAAA, thoracoabdominal aortic aneurysm.
Continuous data are expressed as mean standard deviation and categoric
ata as number (%).
Available in 160 COPD and 325 non-COPD patients.
Available in 162 COPD and 56 non-COPD patients.
Available in 160 COPD and 56 non-COPD patients.
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The method of anesthesia used was similar across both
groups, as was the need for reintubation and tracheostomy
(Table III). Group 1 had a longer duration of stay in the
ICU (P  .02) and a longer overall hospital length of stay
(P  .01). The time to extubation was also longer in the
COPD group, although this was not statistically significant
(P  .07).
Survival analysis
The mean follow-up time was 39.5  30.9 months.
There were no differences in the perioperative (30-day)
survival (P .8; Table IV). Estimated overall survival at 12,
36, and 60 months was, respectively, 82%, 60%, and 41%
for group 1 and 89%, 74%, and 58% for group 2 (log-rank,
P  .0001; Fig 1).
During the follow-up period, 58 of 289 COPD pa-
tients (20%) and 46 of 616 of non-COPD patients (7%)
died of pulmonary-specific causes (log-rank, P .0001; Fig
2). Nonpulmonary-related deaths were similar between the
two groups (log-rank, P .47; Fig 3). Of note, among the
known causes of nonpulmonary-related deaths, half oc-
curred as a result of cardiac issues in both groups: 31 of 62
(50%) in COPD patients vs 74 of 153 (48%) in non-COPD
patients.
A decreasing survival trend (log-rank, P  .08) was
noted when survival was analyzed within the context of
the severity grade for COPD patients (Fig 4, A). How-
ever, combining patients with GOLD classifications III
and IV resulted in a considerable survival disadvantage
compared with patients with GOLD classifications I and
II and patients who did not have COPD (group 2), with
the inflection point of survival discrepancy occurring at
4.2 years (Fig 4, B). The comparison of outcomes be-
tween groups 1 and 2 correlates well with our previously
published scoring system intended to predict long-term
Table III. Perioperative and postoperative variables and
outcomes
Outcomesa
COPD No COPD
P(n  289) (n  616)
Type of anesthesia
General 148 (51) 306 (50) .3
Epidural 138 (48) 288 (47)
Intravenous sedation 4 (1) 20 (3)
Time to extubation, min 380 (275-770) 340 (260-600) .07
Length of stay, days
Intensive care unit 3 (1-5) 2 (1-4) .02
Hospital 5 (3-7) 4 (3-6) .01
Reintubation 26 (9) 41 (7) .2
Tracheostomy 9 (3) 19 (3) .9
Aortic reinterventions 66 (23) 152 (25) .5
COPD, Chronic obstructive pulmonary disease.
aContinuous variables are expressed as median (interquartile range) and
categoric variables as number (%).survival in high-risk aneurysm patients.16 In that scoring cystem, the presence of COPD accounted for 10% of the
verage score, and the need for supplemental home
xygen, 18% of the score. The combined hazard ratio for
OPD and the use of home oxygen was 3.0 (95%
able IV. Analysis of patient deaths with respect to
tiology
utcomes
COPD No COPD
P
(n  28) (n  616)
No. (%) No. (%)
eath
Perioperativea 10 (3) 16 (3) .8
Late aortic-relateda 6 (2) 8 (1) .4
ll-causea 144 (50) 256 (42) .005
Pulmonary 58 (20) 46 (7) .04
Cardiac 31 (11) 74 (12)
Renal 5 (2) 12 (2)
Vascular 0 9 (2)
Gastrointestinal 5 (2) 7 (1)
Neurologic 9 (3) 22 (4)
Other causes 12 (4) 29 (5)
Unknown 24 (8) 57 (9)
ulmonary-specifica 58 (20) 46 (7) .0001
Perioperative pulmonary 0 0
Late pulmonary 58 (20) 46 (7)
Pulmonary failure/end-stage
COPDb 38 (65) 14 (30) .01
Lung cancer 7 (12) 11 (24)
Pneumonia/sepsis 12 (21) 14 (30)
ARDS 1 (2) 2 (4)
Pleural effusion 0 3 (7)
Pulmonary embolism 0 1 (2)
Pulmonary fibrosis 0 1 (2)
RDS, Acute respiratory distress syndrome; COPD, chronic obstructive
ulmonary disease.
Percentages with reference to the total number of patients within the
ohort.
Percentages with reference to the total number of pulmonary specific
eaths.
ig 1. Comparison of overall survival between patients at risk,
ith and without chronic obstructive pulmonary disease (COPD).
haded areas show the 95% confidence limits.onfidence interval, 1.8-5.2).
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Volume 56, Number 4 Qureshi et al 915Factors associated with a decreased patient survival
Overall population. On multivariate analysis, older
patients, low GFR, low hematocrit, more extensive ana-
tomic repairs, and larger baseline aortic diameters were all
independently associated with decreased survival, with the
presence of COPD showing a trend toward decreased
survival (P .07). On univariate analysis, two specific PFT
variables were noted to detrimentally affect survival: a low
FEV1 and a low forced expiratory flow in the middle 50%
(FEF25%-75%; Table V, A [online only]; Table V, B).
COPD patients. Older patients, low hematocrit, and
extensive anatomic repairs were associated with decreased
survival onmultivariate analysis. The need for supplemental
home oxygen did not have an independent effect on late
survival (P .9). Again, on univariate analysis, a low FEV1
and a low FEF were noted to detrimentally affect
Fig 2. Comparison of pulmonary-specific mortality between pa-
tients with and without chronic obstructive pulmonary disease
(COPD). Shaded areas show the 95% confidence limits.
Fig 3. Comparison of nonpulmonary-related mortality between
patients with and without chronic obstructive pulmonary disease
(COPD). Shaded areas show the 95% confidence limits.25%-75%
survival (Table VI, A [online only]; Table VI, B). Cecondary interventions
There were no differences in the requirement for sec-
ndary interventions between the two groups (log-rank,
 .93; Fig 5).
OPD, aneurysm sac behavior, and endoleak analysis
Despite a similar distribution of baseline aortic diame-
ers, differences were noted with respect to morphologic
hanges after endovascular repair. The rate of sac shrinkage
as significantly greater for group 1 patients (5.56 vs 3.90
m/y; P  .001; Fig 6). Of note, group 1 had a lower
ncidence of endoleaks (P  .01), but the distribution of
ype of endoleaks was similar between the two groups
P  .9).
The rate of sac shrinkage was 4.74 mm/y in the
bsence of endoleaks vs 3.10 mm/y with endoleak (P 
0001) for the population as a whole and 5.06 vs 3.50
m/y (P  .001) for COPD patients. However, a
urther analysis confirmed an independent association of
ig 4. A, Comparison of overall survival among the four Global
nitiative for Chronic Obstructive Lung Disease (GOLD) catego-
ies. B, Comparison of overall survival in GOLD groups I  II vs
II  IV and in patients without chronic obstructive pulmonary
isease (COPD). Shaded areas show the 95% confidence limits.OPD with beneficial sac behavior after adjusting for
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VII).
DISCUSSION
The ability to repair aneurysms with an endovascular
approach has revolutionized patient management, with a
primary benefit in decreasing pulmonary morbidity when
compared with conventional procedures. Although EVAR
was initially applied and advocated for patients considered
to be high risk for an open surgical procedure, randomized
Table V. B, Multivariable analysis for the primary
outcome (overall mortality) for the entire study
population (n  905)
Variables
Multivariable HR
(95% CI) P
COPD 1.3 (1.0-1.7) .07
Age, per 5-year increase 1.2 (1.1-1.3) .0003
Male sex 0.9 (0.6-1.2) .3
Use of oxygen at home 0.8 (0.4-1.8) .6
GFR, per 10-unit increase 0.9 (0.9-1.0) .01
Hematocrit, per 5-unit increase 0.9 (0.8-1.0) .01
Aortic diameter, per 1-cm increase 1.2 (1.1-1.3) .00003
Extent of aneurysm repair .04
TAAA 1.2 (0.9-1.6)
Juxtarenal 0.8 (0.6-1.0)
Infrarenal 1
Medication use
Aspirin 0.8 (0.6-1.0) .06
-blocker 1.0 (0.7-1.2) .7
Statin 0.8 (0.6-1.0) .05
Propensity score . . . .2
CI, Confidence interval; GFR, glomerular filtration rate; HR, hazard ratio;
TAAA, thoracoabdominal aortic aneurysm.
a841 patients with 364 events.
Table VI. B, Multivariable analysis for the primary
outcome (overall mortality) within chronic obstructive
pulmonary disease (COPD) patients (n  289)a
Variables
Multivariable HR
(95% CI) P
Age, per 5-year increase 1.2 (1.0-1.4) .02
Male sex 0.7 (0.5-1.1) .1
History of cerebrovascular disease 1.3 (0.8-2.1) .2
Use of oxygen at home 0.9 (0.2-3.4) .9
GFR, per 10-unit increase 1.0 (0.9-1.1) .9
Hematocrit, per 5-unit increase 0.8 (0.7-1.0) .02
Aortic diameter, per 1-cm
increase 1.1 (1.0-1.3) .08
Extent of aneurysm repair .03
TAAA 0.9 (0.6-1.4)
Juxtarenal 0.5 (0.3-0.8)
Infrarenal 1
Aspirin use 1.0 (0.7-1.5) .9
Propensity score — .4
CI, Confidence interval; GFR, glomerular filtration rate; HR, hazard ratio;
TAAA, thoracoabdominal aortic aneurysm.
a146 patients with 62 events.trials found little short-term survival benefit in higher-risk watients compared with medical therapy.17 Only recently
ave long-term data become available demonstrating a
onsiderable mortality benefit for high-risk patients treated
ig 5. Comparison of freedom from secondary interventions
etween patients with and without chronic obstructive pulmo-
ary disease (COPD). Shaded areas show the 95% confidence
imits.
ig 6. Comparison of shrinkage rate of maximum aortic diameter
etween patients with and without chronic obstructive pulmonary
isease (COPD). Shaded areas show the 95% confidence limits.
able VII. Multivariable association between chronic
bstructive pulmonary disease (COPD) and shrinkage
ate, endoleak, smoking, and aspirin use
ariable
Multivariable
OR (95% CI) P
ate of aneurysm sac shrinkage
(per 1 mm/y) 1.06 (1.00-1.12) .03
ndoleak vs none 0.8 (0.6-1.2) .3
moking vs none 2.7 (1.7-4.4) .0001
spirin use vs none 0.8 (0.6-1.0) .06
I, Confidence interval; OR, odds ratio.ith EVAR in contrast to medical therapy.18 Although
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tive manner in which patients were classified into surgically
fit or unfit categories leaves clinicians with little guidance
about optimal patient selection to achieve better perioper-
ative and long-term results. Previous reports from our
institution have focused on other risk factors and morbid-
ities (cardiac, renal, or spinal cord ischemia).9,19-21 The
intention of this report was to better define the periopera-
tive risks and long-term benefits of EVAR in the pulmonary
challenged patient.
Poor pulmonary function is likely the most common
risk factor deterring patients and clinicians from pursuing
an open repair when a thoracotomy or thoracoabdominal
incision is required. The absence of body cavity incisions
likely will diminish the risk of any sort of pulmonary com-
promise, including long-term ventilator needs. In most
series of open TAAA and descending thoracic aneurysm
(DTA) repairs, the most common postoperative complica-
tions are respiratory.22-24 Etz et al25 reported an incidence
of 27% who required ventilatory support 48 hours after
open TAAA and DTA repairs, and 12% of these patients
eventually died. Tracheostomy after TAAA and DTA repair
occurs in 4% to 9% of patients,26 most of whom suffer from
baseline pulmonary dysfunction, and this complication has
been reported to be associated with a highmortality rate. In
a series of 1414 patients reported by Svensson27 and
Money,28 112 (8%) had pulmonary complications requir-
ing tracheostomy, and 45 (40%) died in the hospital.
It is obvious from these data that the detrimental
impact of endovascular procedures on pulmonary function
is considerably less than that of open surgery. There were
no differences in short-term survival and only slightly lon-
ger intubation times and hospital stays in patients with
severe lung disease, whereas the need for tracheostomy was
exceedingly low and similar between groups 1 and 2 (3%
each), with a subanalysis of EVAR patients only demon-
strating an even lower tracheostomy rate of 1.4%. If the
perioperative differences between COPD patients and non-
COPD patients are neutralized, then the sole question that
confronts clinicians caring for aneurysm patients will be
whether there exists an overall survival benefit justifying
aneurysm repair.
An overall assessment of the cause of death will provide
some clues about how to optimally pick patients. It is not
surprising that despite a slightly younger age and better
renal function than non-COPD patients, the overall sur-
vival for patients in group 1 was lower than in group 2. The
presence of a greater number of pulmonary deaths in group
1 of 20% compared with 7% in group 2 is intuitively
obvious. Yet, when pulmonary deaths are eliminated from
the survival analysis from both groups, the survival curves
become nearly identical (Fig 3). Cardiac deaths predomi-
nate the mortality statistics in both groups at a nearly equal
level. Thus, any potential treatment directed at improving
lung function in COPD patients should prolong life expec-
tancy in this subgroup of EVAR patients, and attention
must be focused in this direction. Of note, -blockers are
not used in patients with significant lung disease owing to sheir bronchoconstrictive effect. Thus, any survival benefit
hat may occur by -blocker management will not be
njoyed by COPD patients, an effect that may further
ompound differences.
Survival differences must also be viewed in the context
f aneurysm rupture risk. It has been well documented that
OPD, along with aneurysm size, hypertension, and fe-
ale sex, all increase the risk of rupture of a given aneu-
ysm.29 The etiology of this may relate to the link with
moking, which causes an activation of neutrophil-derived
lastase (which is often elevated in COPD patients) that is
resent in both the lungs and aorta, resulting in degrada-
ion of elastin in both the aortic wall and lung.30,31 Others
onsider the relative alkaline state to be detrimental with
espect to collagen degradation. The balance between an
ncreased rupture risk and decreased long-term survival
ust be viewed in the context of an individual patient until
e have more specific data about how to affect rupture risk
n this population.
An increasing age, lower GFR, lower hematocrit, larger
ortic aneurysm diameter and extent of aneurysm repair,
long with COPD and some other factors, in various com-
inations, are associated with poor outcomes in patients
ndergoing EVAR.16,32 Anemia has been associated with
ncreased mortality,33,34 an observation strengthened by
ur analysis, both overall and within COPD patients. How-
ver, anemia and decreasing renal function have multiple
auses that were difficult to elucidate in this patient popu-
ation.
PFT results can provide specific data on individual
atients that can be related to outcomes in this series.35-37
low FEV1 and FEF25%-75% were univariably associated
ith increased death, both in the overall and COPD pop-
lation. However, because PFT results were obtained only
n patients with baseline pulmonary dysfunction, these
arameters could not be used in the final multivariable
nalysis. Surprisingly, the need for supplemental home
xygen was not independently associated with early or
ate survival. This being said, patients with extremely poor
ulmonary function were likely not even offered EVAR.
lso, the hazard ratio in the total population for home
xygen use was 0.8, which is 1.0. This can be explained
y the fact that this is a high-risk study population; thus, it
s possible that the pulmonary disease qualifying the patient
s high risk is less of a negative determinant on survival than
ther comorbidities such as severe cardiac or renal issues.
hese results indicate that EVAR/eTAAA can be per-
ormed in patients with severe COPD, even when supple-
ental home oxygen after pulmonary optimization is re-
uired.
Mortality risk is higher among patients who have mod-
rate or severe COPD identified by baseline spirometry
ata.38 As shown by the Kaplan-Meier analysis in our study,
decreasing survival trend, not meeting statistical signifi-
ance, was noted over the course of patient follow-up
ithin the COPD cohort with increasing severity of the
isease. So, even though COPD itself does not affect
urvival in a strict statistical manner, the presence and the
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survival, with survival discrepancy occurring at 4.2 years
between the two groups.
It is very interesting that multiple studies have noted
the favorable effect that COPD has on EVAR surrogate
(radiographic) outcomes.39 A lower endoleak rate and
greater speed of sac shrinkage are both perceived as optimal
situations. That is not to say that we should encourage our
patients to smoke after EVAR, but there is clearly an effect
of smoking on decreasing the risk for persistent sac flow40
as well as on the speed of aneurysm resorption. Is this due
to a higher incidence of peripheral vascular disease, perhaps
resulting in smaller lumbar collaterals or an aortic wall that
is partially ischemic? Are there specific effects of nicotine on
the blood vessels resulting in constriction of perianeurysm
small vessels leading to a higher rate of side-branch occlu-
sion? It will be interesting to further evaluate the mecha-
nisms; as such, discoveries may be applicable to non-COPD
patients and provide them with improved morphologic
results.
As with any nonrandomized trial, certain limitations
exist in our study. The benefit of a prospective study is that
there was attention to detail with respect to collection of
preoperative data relating to pulmonary function and de-
tailed collection of early and late adverse (pulmonary)
events. The patient accountability in these studies is quite
high (80% at 2 years), yet often, despite questioning,
patients with COPD may develop pulmonary complica-
tions that are expected in their minds, and thus we are not
informed. Furthermore, patients with mild or no COPD
rarely underwent PFT, which left us with incomplete pul-
monary data for the entire patient cohort. Although many
surgeons advocate routine PFTs before aneurysm repair
(particularly TAA repair), we found this hard to justify in
light of the relatively low risk of perioperative pulmonary
issues. The absence of PFT studies in some COPD patients
made it challenging to directly apply the GOLD criteria for
severity stratification, which were modified slightly to ac-
count for such patients.
CONCLUSIONS
The effect of chronic, even severe, pulmonary disease in
patients being treated with EVAR of AAA or TAA is
minimal during the perioperative period. However, the life
expectancy for an aneurysm patient with COPD is less than
that of an aneurysm patient without COPD. The magni-
tude of the difference is partially quantified by an assess-
ment of the FEV1 and FEF25%-75%. Clearly, patients with
more severe COPD (GOLD classification III and IV) fare
worse than those with less severe pulmonary disease, but
the causes of death in both groups were similar. It is critical
that attention be directed to optimizing the treatment of
chronic lung disease after EVARwith the intent of optimiz-
ing results.
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population (n  905)
Variablesa
Yes
(n  40
COPD 144 (36
Age, years (per 5-year increase) 76.3  7
Male sex 327 (86
Smoking 339 (91
Currently smoking 68 (18
Past smokers 271 (72
Never smoked 35 (9)
Diabetes 67 (17
History of
Coronary artery disease 176 (44
Hypertension 294 (74
Cerebrovascular disease 73 (18
Peripheral vascular disease 40 (10
Ejection fraction, % (per 5% increase) 45.1  1
Ejection fraction 30% 36 (19
FEV1 (per 200-mL increase) 1.5  0
FEV1 1 L 21 (23
FEF25%-75% (per 1-unit increase) 0.7  0
FEF25%-75% 30% of expected 57 (65
Use of oxygen at home 82 (20
History of lung cancer 16 (4)
BMI, kg/m2 (per 5-unit increase) 25.0  8
GFR, mL/min/1.73 m2 (per 10-unit increase) 60.2  2
GFR 40 mL/min/1.73 m2 80 (20
GFR 60 mL/min/1.73 m2 208 (53
Hematocrit (per 5-unit increase) 40.2  5
Aortic diameter, cm (per 1-cm increase) 6.6  1
Extent of aneurysm repair
TAAA 99 (25
Juxtarenal 87 (22
Infrarenal 214 (54
Medication use
Aspirin 190 (48
-blocker 173 (43
Statin 179 (45
BMI, Body mass index; CI, confidence interval; GFR, glomerular filtration
aContinuous data are shown as mean  standard deviation and categoric damary outcome (overall mortality) for the whole study
Overall death
Univariable HR
(95% CI) P0)
No
(n  505)
) 145 (29) 1.6 (1.3-1.9) .00002
.4 73.8  8.0 1.2 (1.1-1.2) .00001
) 428 (85) 0.7 (0.6-0.9) .02
) 424 (90) 1.1 (0.8-1.6) .5
) 103 (22) 1.0 (0.7-1.6) .7
) 321 (68) 1.1 (0.8-1.6)
46 (10) 1
) 93 (18) 0.9 (0.7-1.2) .7
) 197 (39) 0.9 (0.8-1.1) .5
) 405 (80) 1.0 (0.8-1.2) .9
) 88 (17) 1.1 (0.9-1.5) 0.3
) 40 (8) 0.9 (0.7-1.3) .7
5.8 51.2  13.0 1.0 (0.9-1.0) .1
) 26 (9) 1.2 (0.9-1.8) .3
.6 1.8  0.7 0.9 (0.8-1.0) .001
) 21 (16) 1.3 (0.8-2.1) .3
.6 0.9  0.7 0.6 (0.4-0.9) .02
) 69 (54) 1.4 (0.9-2.1) .2
) 61 (12) 1.8 (1.4-2.3) .00001
8 (2) 1.4 (0.8-2.3) .3
.9 26.8  8.0 1.0 (0.9-1.1) .9
4.8 65.5  23.7 0.9 (0.9-1.0) .001
) 65 (13) 1.4 (1.1-1.8) .007
) 211 (42) 1.4 (1.1-1.7) .002
.0 41.4  4.5 0.8 (0.8-0.9) .001
3.5 6.3  12.8 1.2 (1.1-1.3) .00001
.05
) 254 (50) 1.2 (0.9-1.5)
) 131 (26) 0.8 (0.6-1.1)
) 120 (24) 1
) 336 (67) 0.7 (0.6-0.9) .001
) 305 (61) 0.8 (0.6-1.0) .01
) 314 (63) 0.8 (0.6-0.9) .007
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Volume 56, Number 4 Qureshi et al 919.e2Table VI (online only). A, Univariable analysis for the primary outcome (overall mortality) within chronic obstructive
pulmonary disease patients (n  289)
Variablesa
Overall death
Univariable HR
(95% CI) P
mditYes
(n  144)
No
(n  145)
Age, years (per 5-year increase) 74.4  6.4 72.5  6.9 1.2 (1.0-1.4) .01
Male 108 (75) 117 (81) 0.7 (0.5-1.1) .1
Smoking 131 (98) 135 (97) 1.4 (0.3-5.6) .6
Currently smoking 26 (20) 42 (30) 1.1 (0.3-4.7) .4
Past smokers 105 (79) 93 (67) 1.5 (0.4-6.0)
Never smoked 2 (1) 4 (3) 1
Diabetes 19 (13) 28 (19) 0.8 (0.5-1.3) .4
History of
Coronary artery disease 59 (41) 50 (34) 1.1 (0.8-1.6) .5
Hypertension 100 (69) 110 (76) 1.0 (0.7-1.4) .9
Cerebrovascular disease 25 (17) 20 (14) 1.4 (0.9-2.1) .2
Peripheral vascular disease 13 (9) 11 (8) 0.9 (0.5-1.6) .8
Ejection fraction, % (per 5% increase) 47.1  16.2 50.8  11.1 1.0 (0.9-1.0) .3
Ejection fraction 30% 13 (18) 5 (6) 1.6 (0.9-3.0) .3
FEV1 (per 200-mL increase) 1.3  0.5 1.6  0.7 0.9 (0.8-1.0) .01
FEV1 1 L 21 (29) 21 (23) 1.2 (0.7-2.0) .5
FEF25%-75% (per 1-unit increase) 0.5  0.3 0.6  0.4 0.5 (0.3-1.0) .1
FEF25%-75% 30% of expected 54 (77) 66 (74) 1.1 (0.6-2.0) .7
Use of oxygen at home 72 (50) 54 (37) 1.3 (1.0-1.9) .08
History of lung cancer 7 (5) 6 (4) 0.8 (0.4-1.8) .6
BMI, kg/m2 (per 5-unit increase) 24.8  9.5 27.3  8.1 1.0 (0.9-1.1) .9
GFR, mL/min/1.73 m2 (per 10-unit increase) 66.0  25.5 69.6  26.0 1.0 (0.9-1.0) .2
GFR 40 mL/min/1.73 m2 20 (14) 18 (12) 1.2 (0.7-1.9) .5
GFR 60 mL/min/1.73 m2 58 (41) 52 (36) 1.2 (0.9-1.7) .2
Hematocrit (per 5-unit increase) 41.1  5.3 42.0  4.6 0.8 (0.6-0.9) .004
Aortic diameter, cm (per 1-cm increase) 65.6  12.3 63.6  14.1 1.1 (1.0-1.3) .02
Extent of aneurysm repair .2
TAAA 43 (30) 78 (54) 1.1 (0.7-1.6)
Juxtarenal 33 (23) 40 (28) 0.7 (0.5-1.1)
Infrarenal 68 (47) 27 (19) 1
Medication use
Aspirin 65 (45) 90 (62) 0.8 (0.5-1.0) .1
-blocker 50 (35) 75 (52) 0.9 (0.6-1.3) .6
Statin 68 (48) 87 (60) 0.8 (0.6-1.2) .3
GOLD classification
I 7 (5) 16 (112) 1 .3
II 46 (32) 65 (47) 0.9 (0.4-2.0)
III 38 (26) 29 (21) 1.3 (0.6-2.9)
IV 53 (37) 29 (21) 1.3 (0.6-2.8)
BMI, Body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEF25%-50%, forced expiratory flow in the middle 50%; FEV1,
forced expiratory volume in 1 second; GFR, glomerular filtration rate; HR, hazard ratio; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
TAAA, thoracoabdominal aortic aneurysm.
aContinuous data are shown as mean  standard deviation and categoric data as number (%).
